The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors a patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

“Immediately following coronary intervention, a patient with a low ejection fraction is at risk of SCA. Other risk factors, beyond ejection fraction, include renal insufficiency, Killip class II or III, patient age over 65 years, anemia, and multi-vessel disease,” explained Richard A. Packer, Chief Executive Officer of ZOLL. “The LifeVest protects these patients from SCA while their heart recovers.”

The AutoPulse provides automated CPR chest compressions when the heart is no longer effectively circulating blood due to ventricular fibrillation or cardiac standstill. It features an easy-to-use, load-distributing LifeBand®that squeezes the entire chest, improving blood flow to the heart and brain during SCA. The AutoPulse may offer a significant advantage over manual CPR, moving blood more consistently than human providers. The device delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion. Additionally, it offers the benefit of freeing up clinicians to focus on other life-saving interventions.

ZOLL’s IVTM product line offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP®console andfamily of cooling/warming catheters work together to deliver accurate, easy-to-use, and cost-effective control for both cooling and warming applications. The full line of IVTM catheters provides central venous infusion capabilities.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.